The Motley Fool

This penny stock could double in just 2 years

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

4D Pharma (LSE: DDDD) is a speculative UK penny stock that I’d like to add to my portfolio, because I think its share price could double in just two years. I’ll get why I think that, but first let’s just outline what this biotech company does.

4D Pharma is developing live biotherapeutic products (LBPs), a novel class of drug derived from the human microbiome. The microbiome is essentially microbes that live within the human body. Of particular interest for future healthcare are those in the gut. 4D Pharma has a number of drugs in phase II trials across different medical fields including immune-oncology (cancer) and gastro-intestinal (such as treatments for IBS).

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

Why could this penny stock double?

Here’s the interesting part – why could the shares do phenomenally well in the coming 24 months? I expect the move into phase III trials will increase the profile of 4D Pharma with investors, both biotechnology investors and beyond.

I think the company’s US listing, on the NASDAQ exchange, will add significant liquidity and provide money for the company to keep progressing its trials. It has raised £30m and has cash on the balance sheet so future shareholders hopefully shouldn’t get diluted.

Overall though what most makes me think the share price can potentially double in two years is that by 2022, revenue is forecast to be £16.2m, from negligible revenue currently. Analyst forecasts have the shares on a price target of 405p, versus around 84p at the time of writing.

There are massive risks, however. First, there is the risk that drug trials fail, or that progress is slower than investors hope. Another concern is that there could be greater competition as the microbiome is becoming increasingly understood. Although 4D Pharma has raised money from shareholders, if trials do go on longer than expected, the company may ask backers for more money. That would dilute any holding and make it harder to make a profit.

On the balance of risk and reward, though I think 4D Pharma is a penny stock I’d likely add to my portfolio. However, it would be a small position! If things go well and it moves to making revenue, I think the share price could at least double within two years.

Another option?

I think Quarto is another penny stock with huge potential. It’s a very different company. Quarto is an illustrated book publishing and distribution company. The shares trade on a forward price-to-earnings of only seven, indicating the shares could be cheap. The group has aggressively cut debt and been adding cash to the balance sheet in recent years. That could set it up for future growth.

On the other hand, margins are quite small and revenues have been falling in consecutive years since 2017. The group also doesn’t pay a dividend, a potential red flag that management believes the group faces challenges. It could be a high-risk/high-reward penny stock that I’ll research further before deciding whether to add to my portfolio.

FREE REPORT: Why this £5 stock could be set to surge

Are you on the lookout for UK growth stocks?

If so, get this FREE no-strings report now.

While it’s available: you'll discover what we think is a top growth stock for the decade ahead.

And the performance of this company really is stunning.

In 2019, it returned £150million to shareholders through buybacks and dividends.

We believe its financial position is about as solid as anything we’ve seen.

  • Since 2016, annual revenues increased 31%
  • In March 2020, one of its senior directors LOADED UP on 25,000 shares – a position worth £90,259
  • Operating cash flow is up 47%. (Even its operating margins are rising every year!)

Quite simply, we believe it’s a fantastic Foolish growth pick.

What’s more, it deserves your attention today.

So please don’t wait another moment.

Get the full details on this £5 stock now – while your report is free.

Andy Ross owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.